Recherchemedicale.com
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes tumoraux
Oncogènes
Proto-oncogènes
Gènes fms
Gènes fms : Questions médicales fréquentes
Diagnostic
5
Séquençage génétique
Tests de laboratoire
Tests génétiques
Symptômes
Marqueurs biologiques
Anomalies génétiques
Symptômes
5
Troubles immunitaires
Anomalies sanguines
Mutations génétiques
Symptômes
Gestion des symptômes
Permanence
Prévention
5
Prévention
Mutations génétiques
Dépistage
Familles à risque
Conseil génétique
Familles à risque
Tests génétiques
Porteurs de mutations
Mode de vie
Santé globale
Traitements
5
Thérapies ciblées
Transfusions sanguines
Médecine personnalisée
Profil génétique
Essais cliniques
Thérapies
Efficacité des traitements
Réponse au traitement
Effets secondaires
Réactions allergiques
Complications
5
Complications
Troubles hématologiques
Gravité
Attention médicale
Gestion des complications
Suivi médical
Complications à long terme
Suivi
Facteurs de risque
5
Antécédents familiaux
Expositions environnementales
Hérédité
Mutations génétiques
Tests génétiques
Évaluation des risques
Mode de vie
Réduction des risques
Groupes ethniques
Facteurs géographiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes fms : Questions médicales les plus fréquentes",
"headline": "Gènes fms : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes fms : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-29",
"dateModified": "2025-01-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes fms"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Proto-oncogènes",
"url": "https://recherchemedicale.com/mesh/D011519",
"about": {
"@type": "MedicalCondition",
"name": "Proto-oncogènes",
"code": {
"@type": "MedicalCode",
"code": "D011519",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.375.500.791"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes fms",
"alternateName": "Genes, fms",
"code": {
"@type": "MedicalCode",
"code": "D016236",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Annika Schulz",
"url": "https://recherchemedicale.com/author/Annika%20Schulz",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany."
}
},
{
"@type": "Person",
"name": "Marcus Brand",
"url": "https://recherchemedicale.com/author/Marcus%20Brand",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany."
}
},
{
"@type": "Person",
"name": "Seyed-Omar Zaraei",
"url": "https://recherchemedicale.com/author/Seyed-Omar%20Zaraei",
"affiliation": {
"@type": "Organization",
"name": "Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates."
}
},
{
"@type": "Person",
"name": "Taleb H Al-Tel",
"url": "https://recherchemedicale.com/author/Taleb%20H%20Al-Tel",
"affiliation": {
"@type": "Organization",
"name": "Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates. Electronic address: taltal@sharjah.ac.ae."
}
},
{
"@type": "Person",
"name": "Mohammed I El-Gamal",
"url": "https://recherchemedicale.com/author/Mohammed%20I%20El-Gamal",
"affiliation": {
"@type": "Organization",
"name": "Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address: malgamal@sharjah.ac.ae."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "M2 macrophage-related gene signature in chronic rhinosinusitis with nasal polyps.",
"datePublished": "2022-11-17",
"url": "https://recherchemedicale.com/article/36466903",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.1047930"
}
},
{
"@type": "ScholarlyArticle",
"name": "The latest perspectives of small molecules FMS kinase inhibitors.",
"datePublished": "2023-09-07",
"url": "https://recherchemedicale.com/article/37708796",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2023.115796"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fms -like tyrosine kinase 3 positive acute myeloid leukemia.",
"datePublished": "2023-09-05",
"url": "https://recherchemedicale.com/article/37820093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/CCO.0000000000000993"
}
},
{
"@type": "ScholarlyArticle",
"name": "Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment.",
"datePublished": "2024-01-09",
"url": "https://recherchemedicale.com/article/38204232",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2174/0109298673277543231205072556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure.",
"datePublished": "2024-07-09",
"url": "https://recherchemedicale.com/article/38980212",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ejhf.3368"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://recherchemedicale.com/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://recherchemedicale.com/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://recherchemedicale.com/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://recherchemedicale.com/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://recherchemedicale.com/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes tumoraux",
"item": "https://recherchemedicale.com/mesh/D052138"
},
{
"@type": "ListItem",
"position": 8,
"name": "Oncogènes",
"item": "https://recherchemedicale.com/mesh/D009857"
},
{
"@type": "ListItem",
"position": 9,
"name": "Proto-oncogènes",
"item": "https://recherchemedicale.com/mesh/D011519"
},
{
"@type": "ListItem",
"position": 10,
"name": "Gènes fms",
"item": "https://recherchemedicale.com/mesh/D016236"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes fms - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes fms",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-02-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes fms",
"description": "Comment diagnostiquer une mutation des gènes fms ?\nQuels tests sont utilisés pour les gènes fms ?\nLes gènes fms sont-ils testés en routine ?\nQuels spécialistes effectuent le diagnostic ?\nY a-t-il des marqueurs associés aux gènes fms ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes fms",
"description": "Quels sont les symptômes d'une mutation fms ?\nLes symptômes varient-ils selon les mutations ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes apparaissent-ils à un âge précis ?\nLes symptômes sont-ils réversibles ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes fms",
"description": "Peut-on prévenir les mutations des gènes fms ?\nLe dépistage précoce est-il recommandé ?\nY a-t-il des conseils pour les familles à risque ?\nLes tests génétiques sont-ils utiles en prévention ?\nDes changements de mode de vie peuvent-ils aider ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes fms",
"description": "Quels traitements sont disponibles pour les mutations fms ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour les gènes fms ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes fms",
"description": "Quelles complications peuvent survenir avec les gènes fms ?\nLes complications sont-elles graves ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes fms",
"description": "Quels sont les facteurs de risque pour les mutations fms ?\nLes facteurs de risque sont-ils héréditaires ?\nY a-t-il des tests pour évaluer les facteurs de risque ?\nLes facteurs de risque peuvent-ils être modifiés ?\nLes facteurs de risque varient-ils selon les populations ?",
"url": "https://recherchemedicale.com/mesh/D016236#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une mutation des gènes fms ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par séquençage génétique et tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes fms ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et de séquençage sont couramment utilisés pour détecter les mutations."
}
},
{
"@type": "Question",
"name": "Les gènes fms sont-ils testés en routine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests des gènes fms ne sont pas systématiques et dépendent des symptômes."
}
},
{
"@type": "Question",
"name": "Quels spécialistes effectuent le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les généticiens et les hématologues sont souvent impliqués dans le diagnostic."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs associés aux gènes fms ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs spécifiques peuvent indiquer des anomalies des gènes fms."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une mutation fms ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles immunitaires et des anomalies sanguines."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les mutations ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction du type de mutation présente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections fréquentes et des saignements anormaux sont à surveiller."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à un âge précis ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître à tout âge, souvent durant l'enfance."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les mutations des gènes fms ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de méthode de prévention pour ces mutations génétiques."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il recommandé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce peut être recommandé pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils pour les familles à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les familles à risque devraient consulter un conseiller en génétique pour des conseils."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles en prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent aider à identifier les porteurs de mutations."
}
},
{
"@type": "Question",
"name": "Des changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que les changements de mode de vie ne préviennent pas les mutations, ils peuvent améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les mutations fms ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies ciblées et des transfusions sanguines."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour les gènes fms ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent de nouvelles thérapies pour ces mutations."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de mutation et la réponse individuelle au traitement."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions allergiques et des infections."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les gènes fms ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles hématologiques et des infections récurrentes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être graves et nécessiter une attention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical régulier et des traitements appropriés."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent persister et nécessiter un suivi à long terme."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les mutations fms ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines expositions environnementales peuvent être des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils héréditaires ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations des gènes fms peuvent être héréditaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent aider à évaluer les facteurs de risque chez les individus."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque peuvent-ils être modifiés ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains facteurs de risque, comme le mode de vie, peuvent être modifiés pour réduire les risques."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque varient-ils selon les populations ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les facteurs de risque peuvent varier selon les groupes ethniques et géographiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/01/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates. Electronic address: taltal@sharjah.ac.ae.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address: malgamal@sharjah.ac.ae.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry; hkitaura@m.tohoku.ac.jp.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry.
Publications dans "Gènes fms" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachussetts, USA.
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Publications dans "Gènes fms" :
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common sinonasal inflammatory disorder with high heterogeneity. Increasing evidence have indicated that the infiltration of macrophages especiall...
The expression datasets of GSE136825 and GSE179265 were download from Gene Expression Omnibus (GEO) database and merged. Then, CIBERSORT and weighted gene co-expression network analysis (WGCNA) algori...
A total of 92 DEGs associated with M2 macrophages were identified for further analysis. The results of Gene ontology (GO) and Kyoto Encyclopedia of genes and genomes (KEGG) analyses illustrated that M...
These findings yield new insights into the hub genes and mechanisms related to M2 macrophages in the pathogenesis of CRSwNP. Further studies of these hub genes would help better understand the disease...
FMS kinase is a type III tyrosine kinase receptor that plays a central role in the pathophysiology and management of several diseases, including a range of cancer types, inflammatory disorders, neurod...
Fms -like tyrosine kinase 3 (FLT3) mutations are common in newly diagnosed patients with acute myeloid leukemia (AML). They are associated with a high risk of relapse. The identification of FLT3 mutat...
This article will analyze recent advances for FLT3-mutant AML, focusing on front-line therapy and post-transplant maintenance....
Novel drug combinations and strategies against FLT3 mutated AML are currently under investigation and will be the focus of future studies. The development of more selective and potent FLT3 inhibitors ...
FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated gene in acute myeloid leukemia. As a receptor tyrosine kinase (RTK), FLT3 plays a role in the proliferation and differentiation of hematopoietic...
In this paper, PubMed and SciFinder® were used as a tool; the publications about "FLT3 inhibitor" and "Acute myeloid leukemia" were surveyed from 2014 to the present with an exclusion of those publish...
In this study, the structural characterization and biological activities of representative FLT3 inhibitors were summarized. The major challenges and future directions for further research are discusse...
Recently, numerous FLT3 inhibitors have been discovered and employed in FLT3-mutated AML treatment. In order to overcome the drug resistance caused by FLT3 mutations, screening multitargets FLT3 inhib...
Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), components of the vascular endothelial growth factor (VEGF) system, play key roles in angiogenesis. Reports of elevated ...
ELISA assays for sFlt-1, PlGF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed on baseline plasma samples from the PEOPLE cohort (n = 890), a study of outcomes among patients a...
Plasma sFlt-1 concentrations have potential as an independent predictor of survival and may be complementary to established prognostic biomarkers in HF....
Preeclampsia (PE) is a serious complication, and soluble fms-like tyrosine kinase (sFLT1) released from the placenta is one of the causes of PE pathology. Trophoblasts are the primary source of sFLT1;...
Pulmonary tuberculosis (PTB) diagnosis relies on sputum examination, a challenge in sputum-scarce patients. Alternative non-invasive sampling methods such as face mask sampling (FMS) have been propose...
To evaluate the value of FMS for PTB diagnosis by assessing its agreement with sputum samples processed by GeneXpert MTB/RIF (Ultra)(Xpert) testing, and describe FMS sensitivity and specificity....
This was a prospective study conducted at the Carrière TB clinic in Guinea. Presumptive TB patients willing to participate were asked to wear a surgical mask containing a polyvinyl alcohol (PVA) strip...
One hundred fifty patients participated, of whom 148 had valid results for both mask and sputum. Sputum smear microscopy was positive for 47 (31.8%) patients while sputum-Xpert detected MTB in 54 (36....
In our setting, Xpert testing on FMS did not yield a high level of agreement to sputum sample....
FMS-like tyrosine kinase (FLT3) has become the legitimate molecular therapeutic target for acute myeloid leukemia therapy. Though FLT3 inhibitors have impact on disease progression, drug resistance in...
Vitronectin is an abundant multifunctional glycoprotein found in serum, the extracellular matrix, and bone, and is involved in diverse physiological processes. Here, we developed a new bioactive dimer...
The present systematic review analyses the role of soluble fms-like tyrosine kinase-1 (sFLT-1) as an indirect biomarker of endothelial dysfunction in sepsis or septic shock from articles published in ...
A systematic review of studies studying sFLT-1 monitoring in intensive care units in adults with sepsis or septic shock vs. controls for sepsis diagnosis and prognosis has been carried out (PROSPERO C...
The endothelial dysfunction of sepsis is one of the keys to the development of the disease. VEGF binds to sFLT-1 acting as a competitive inhibitor of VEGF signalling in endothelial cells and thus neut...
It is evident that sepsis is based on endothelial dysfunction. sFLT-1 is one of the main biomarkers of microvascular alteration and is a predictive diagnostic and prognostic biomarker....